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Short, Cool, and Well Oxygenated – HOPE for Kidney
Transplantation in a Rodent Model
Philipp Kron, MD, Andrea Schlegel, MD, Olivier de Rougemont, MD, Christian Eugen Oberkofler, MD,
Pierre-Alain Clavien, MD, PhD, and Philipp Dutkowski, MD
Objectives: The aim of this study was to investigate novel and easily
applicable preservation perfusion techniques in kidney grafts obtained from
donors after circulatory death (DCD).
Background: A novel perfusion approach, hypothermic oxygenated per-
fusion (HOPE), used for DCD liver grafts, is based on cold perfusion for
1 hour by an oxygenated solution before implantation. Here, we aimed to test
HOPE in a rodent model of kidney grafts associated with substantial warm
ischemia.
Methods: Rat kidneys were exposed to 30minutes in situ warm ischemia,
without application of heparin. Kidneys were removed and cold stored for 4
and 18 hours, mimicking DCD organ procurement and conventional preser-
vation. In additional experiments, kidneys were normothermically perfused
with oxygenated blood for 1 hour after cold storage. In a third group, kidneys
were perfused by HOPE for 1 hour after cold storage. In each group,
orthotopic kidney transplantation was performed after recipient nephrectomy.
Results: HOPE-treated DCD kidneys showed dramatically better function
after transplantation, than cold-stored grafts in terms of nuclear injury,
macrophage activation, endothelium activation, tubulus damage, and graft
function. A short period of warm oxygenated perfusion before implantation
improved graft quality as compared with cold storage, but was significantly
less effective in all endpoints compared with HOPE. The effect of HOPE was
dependent on perfusate oxygenation in the cold.
Conclusions: HOPE of DCD kidneys was superior to other clinically used
preservation approaches, consistent to earlier results in livers. On the basis of
this, we assume a strong and generalized effect on solid organ viability by
HOPE before transplantation. These results justify a clinical trial.
Keywords: DCD kidney, hypothermic oxygenated perfusion, kidney
transplantation, normothermic oxygenated kidney perfusion, survival
(Ann Surg 2016;xx:xxx–xxx)
O rgan transplantation continues to be limited by a severe short-age of donors. In response to this, there has been a worldwide
increase in the use of compromised donors, and a significant
proportion of transplanted organs are currently taken from extended
criteria donors (ECDs)1,2 and also donation after circulatory death
(DCD).3 However, these organs generally suffer from a higher risk of
dysfunction after implantation, which trigger acute rejection and
impair long-term graft survival.3 Therefore, new concepts of pres-
ervation, for example, machine perfusion instead of conventional
cold static storage, have been suggested to improve graft viability,
differing mainly in perfusate conditions, including temperature and
timing of perfusion.4–7
In this context, our group developed a short-term 1 to 2-hour
Hypothermic Oxygenated Perfusion (HOPE), applied after cold
storage in liver transplantation.8–13 In various animal transplant
models, we showed a high protective effect of HOPE.8–11 In
addition, recent human application of HOPE rescued extended
DCD livers, exposed to long donor warm ischemia,12 and was
superior than matched, un-perfused DCD liver grafts.13 On the basis
of the success of HOPE in livers, we aimed to test HOPE in kidneys.
In a second step, we compared HOPE with a normothermic endi-
schemic perfusion approach, which has recently gained much atten-
tion in the UK and Netherlands.5,6,14,15
We chose a standardized rodent DCD kidney transplant
model, associated with substantial donor warm ischemia, and applied
machine perfusion using both techniques against conventional cold
storage with subsequent transplantation.
METHODS
Animals
We used male Brown Norway rats in all experiments. The
animal ethics committee (009/2015) approved all experiments.
Anesthesia during kidney procurement and transplantation was
maintained with isoflurane.
Study Design
According to previous publications,9–11 we opted for a rodent
DCD kidney transplant model, with induction of cardiac arrest by
incision of the diaphragm without prior heparinization or vessel
clamping. We applied 30minutes of asystolic donor warm ischemia
time in all experimental groups and used an established orthotopic
model of kidney transplantation for recipients.16,17 The study
analyses the effect of different machine perfusion strategies on graft
injury and survival.
The following experimental groups were chosen (Supple-
mentary Fig. 1A, http://links.lww.com/SLA/B16):
(1) Control group: Healthy kidneys (non-DCD) were exposed to
minimal cold storage (15minutes UW solution), and sub-
sequently transplanted (No Injury, n ¼ 10). In additional exper-
iments, kidneys were treated before implantation by either 1-
hour normothermic or 1-hour hypothermic perfusion (No injury
and perfusion, n ¼ 5 each).
(2) Cold storage group: Nonperfused DCD kidneys were exposed to
30minutes of in situ warm ischemia and cold stored (CS) for
18 or 4 hours, respectively (UW), and transplanted afterwards
(DCD and CS, n ¼ 8/10).
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(3) Cold storage and normothermic perfusion group: DCD kidneys
were exposed to 30minutes of in situ warm ischemia, followed
by 18 or 4 hours cold storage along with 1 hour perfusion, and
transplanted afterwards (DCD, CS, and normotherm, n ¼ 8/10).
(4) Cold storage and HOPE group: DCD kidneys were exposed to
30minutes of in situ warm ischemia, followed by 18 or 4 hours
cold storage along with 1 hour perfusion, and transplanted
afterwards (DCD, CS, and HOPE, n ¼ 8/10).
(5) Cold storage and hypothermic de-oxygenated perfused (HNPE)
group: DCD kidneys were exposed to 30minutes of in situ warm
ischemia, followed by 18 or 4 hours of cold storage along with
1 hour perfusion with deoxygenated perfusate (¼nitrogenated),
and transplanted afterwards (DCD, CS, and HNPE, n ¼ 8/10).
Surgical Technique Donor
Following laparotomy, a period of 30minutes asystolic warm
ischemia (DCD) was induced by bilateral incision of the diaphragm.
Consecutive induction of a pneumothorax led to hypoxia and sub-
sequent cardiac arrest, mimicking withdrawal of ventilation in the
clinical setting of Maastricht III donors (controlled DCD). The mean
time until cardiac arrest was 9.3  2minutes. Warm ischemia was
defined as the time after cardiac arrest to cold flush, corresponding to
asystolic warm ischemia. Before retrieval, kidneys were flushed in
situ with 6mL heparinized (1U/mL) saline at room temperature
followed by 5mL cold UW solution via aorta (renal artery). Kidneys
were then excised (weight 0.98 0.078 g) and placed in UW solution
(48C). In the perfusion groups, kidneys received stents for the aorta
(renal artery). Ureters of all kidneys were stented (24G).
Surgical Technique Recipient
After machine perfusion, all kidneys were again flushed with
5mL cold UW solution and a cuff was inserted in the renal vein.
Subsequently, kidney transplantation was performed as previously
described.17,18 Before kidney implantation, all recipients underwent
bilateral nephrectomy.16
Normothermic Perfusion
Normothermic kidney perfusion was performed with a hepari-
nized, leukocyte depleted blood perfusate.6 Erythrocytes were iso-
lated out of full rat blood and added to Ringers solution, according
to Nicholson and Hosgood6 (hematocrit 20%, leukocyte count
<5/mm3). The perfusate was supplemented by heparin, Mannitol
10%, Dexamethasone, Prostacyclin, Sodium bicarbonate, Nutriflex
(B. Braun). Kidneys were perfused continuously and pulsatile (190/
min) at 378C through the renal artery (mean arterial pressure 63mm
Hg, range 55 to 75mm Hg) by pressure control. Perfusates were
actively oxygenated ( pO2 55 to 65 kPa) (Supplementary Fig. 1B, C,
http://links.lww.com/SLA/B16).6,19
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FIGURE 1. Preservation injury before and after transplantation of cold-stored DCD kidneys. Cold-stored (18hours) DCD kidneys
(30minutes warm ischemia) were microscopically well preserved at the end of cold storage (A). In contrast, following implantation,
severe injury occurred in terms of oxidized nuclear DNA (8-OHdG), DAMPs release (HMGB-1), Toll-like receptor activation (TLR-4),
and endothelial activation (vWF) (B, C). Reduction of cold storage to 4hours significantly reduced reperfusion injury (B, C).
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Hypothermic Oxygenated Perfusion
HOPE was performed for 1 hour through the renal artery
(aortic patch) with a constant perfusion pressure of <18mm
Hg,20 and active oxygenation ( pO2 60 to 80 kPa). We used 50mL
recirculating Kidney-Perfusion Solution-1 (KPS-1) as perfusate.
Perfusion box and perfusate were cooled to 48C by an open bath
thermostat (Fig. 1B, C). In additional experiments (group 5), perfu-
sate deoxygenation was facilitated by insufflation of nitrogen result-
ing in low pO2 (<2 kPa) (HNPE group).
11
Endpoints
Kidney function and tubular injury were analyzed by NGAL
and creatinine in plasma samples. Oxidative damage of DNA was
detected in perfusate and plasma by 8-hydroxy-2-deoxy Guanosine
(8-OHdG). ATP was measured as previously reported.9,10 Nuclear
injury was measured by release of high mobility group box protein-1.
Quantitative real-time polymerase chain reaction (PCR) was per-
formed (TaqMan gene expression assays) for Toll-like receptor
(TLR)-4, tumor necrosis factor-alpha (TNF-a), high mobility group
box-1 protein (HMGB-1), von Willebrand factor (vWF), endothelin
1 (Edn-1), Hepatocyte growth factor. The following staining
procedures were performed: Haematoxylin-Eosin (H&E)-staining
(tubular injury), TLR-4-staining (Macrophage and tubuli activation),
and vWF (endothelial activation). Histological sampleswere quantified.
Statistical Analysis
Data are presented as mean  standard deviation (SD).
Statistical analysis was performed using the nonparametric Mann-
Whitney-Wilcoxon U test (GraphPad Prism, version 6.0; San Diego,
CA).
RESULTS
Cold Storage of DCD Kidneys
DCD kidneys subjected to 30minutes in situ warm ischemia
and subsequent 18 hours cold storage appeared macro- and micro-
scopically well preserved before implantation with minor tubular cell
injury or endothelial cell activation (Fig. 1A) in spite of massive ATP
depletion during cold storage (Fig. 2D). After transplantation, we
detected severe reperfusion injury in terms of oxidized nuclear DNA
(8-OHdG), release of HMGB-1, increased presence of Toll-like
receptor-4 (TLR-4) positive cells, endothelial activation (vWF),
tubulus injury, and also poor kidney function (Fig. 1B, C). All
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FIGURE 2. Graft injury during 1hours machine perfusion of cold-stored DCD kidneys (4 and 18hours). Normothermic perfusion
resulted in oxidative stress (E) with release of DAMPs (F), and massive activation of TLR-4 on tubuli (B,G), as well as endothelial cell
activation (C) during perfusion. In addition, HSP 70 and PCNA were upregulated during normothermic perfusion (H, I). HOPE
treatment reloaded most effectively cellular ATP (D) and caused neither relevant oxidative stress (E), or DAMPs release (F) or TLR-4/
endothelial activation (B, C, F, G).
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animals died consecutively within 24 hours of surgery. Reduction of
cold ischemia from 18 to 4 hours significantly reduced graft injury in
all endpoints (Fig. 1B, C), correlating to recent reports in human,2,21
but did not prevent from lethal injury in recipients (Fig. 3B).
Cold Storage and Normothermic Oxygenated
Perfusion of DCD Kidneys
As a proof of concept, we tested normothermic perfusion by
an established technique5,6 of healthy non-DCD kidneys, which
resulted in no relevant injury during perfusion and 100 % graft
survival (7 days) after subsequent transplantation (Fig. 3A to C).
In a next step, we treated DCD kidneys after 18 hours cold
storage by 1 hour normothermic perfusion. Cellular adenine nucleo-
tide levels increased significantly by normothermic perfusion com-
pared with cold-stored kidneys (Fig. 2D), reflecting successful restart
of aerobic metabolism. However, we found high amounts of 8-OHdG
and HMGB-1 in the normothermic perfusate (Fig. 2E, F), suggesting
relevant oxidative stress during normothermic perfusion. In parallel,
we documented a high number of TLR-4 positive cells (Fig. 2B),
underlining activation of macrophages and dendritic cells by
danger-associated molecular patterns (DAMPs) release during nor-
mothermic perfusion. Correspondingly, several antioxidative and
regenerative pathways, for example, Heat Shock Protein 70 (HSP
70), proliferating cell nuclear antigen (PCNA), cJNK, were stimu-
lated already during normothermic perfusion due to upregulation of
cellular defense mechanisms by reactive oxygen species (ROS)
release (Fig. 2H, I). Despite this, all animals died within few hours
after subsequent transplantation (18 hours cold storage and 1 hour
normothermic perfusion). Reduction of cold ischemia from 18 to
4 hours reduced significantly oxidative stress, DAMPs release, TLR-
4, and endothelial activation during normothermic perfusion (Fig. 2).
After subsequent implantation, those grafts showed less injury
compared with unperfused 4 hours cold-stored DCD kidneys
(Figs. 4A to F and 5A to E), but recipients died also within 2 to
4 days (Fig. 3B). These results suggest severe inflammation of
cold-stored ischemic (DCD) kidneys already during normothermic
perfusion, in contrast to normothermically perfused nonischemic
(DBD) kidneys.
Cold Storage and Hypothermic Oxygenated
Perfusion of DCD Kidneys
In a third step, we tested our hypothermic perfusion approach,
initially developed for livers. DCD kidneys treated after 18 hours
cold storage by 1 hour HOPE showed minimal release of DAMPs or
reactive oxygen species (8-OHdG) during cold perfusion (Fig. 2E, F)
in spite of high oxygen saturation in the perfusate (60 to 80 kPa,
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FIGURE 3. Graft injury of cold-stored DCD kidneys 1 day after machine perfusion and transplantation. Normothermic perfused
kidney transplants showed less oxidized DNA (A), less HMGB-1 release (B), less tissue TNF-a (D), and less plasma NGAL
concentrations (F) compared with cold storage. HOPE treatment was significantly more effective in terms of oxidative stress,
DAMPs release, and tubulus/endothelial activation (A to F). Importantly, the benefits of HOPE were abrogated in the absence of
perfusate oxygen (HNPE) (A to F). We suggest therefore that mitochondrial repair processes during HOPE are responsible for
decreased release of mitochondrial ROS during reperfusion. Due to less oxidative stress, the amount of released DAMPs is
subsequently also decreased, together with minor downstream activation endothelial cells (G), similarly as observed in HOPE
treated liver grafts.8
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Supplementary Fig. 1, http://links.lww.com/SLA/B16). ATP
increased significantly and higher by HOPE treatment than normo-
thermic perfusion (Fig. 2D). After implantation, all HOPE-treated
kidneys presented with significant less injury compared with
cold storage and normothermic perfusion in terms of 8-OHdG-
and HMGB-1 release, TRL-4 activation, endothelial activation,
and tubulus injury (Figs. 4 and 5). Despite this protection, HOPE
treatment after 18 hours cold storage could not reverse lethal injury.
However, reduction of cold ischemia from 18 to 4 hours resulted in
80% 7-day survival in contrast to cold storage or normothermic
perfusion (Fig. 3B). Histology after 7 days in survivors showed no
fibrosis, low endothelial activation, and normal amount of dendritic
cells (Fig. 3C).
Cold Storage and Hypothermic Deoxygenated
(Nitrogenated) Perfusion of DCD Kidneys
To analyze whether the protective effect of endischemic
HOPE relates to the presence of oxygen in the perfusate, we repeated
hypothermic perfusion experiments with a deoxygenated perfusate.
In contrast to HOPE treatment, kidneys hypothermically perfused
without oxygen after cold storage suffered from high release of ROS
during implantation, with massive activation of macrophages, den-
dritic cells, and endothelial cells, similar as seen in cold-stored and
nomothermically perfused kidneys (Figs. 4 and 5). All recipients
from this experimental group died from graft failure shortly after
implantation (Fig. 3A, B).
DISCUSSION
The use of machine perfusion of organs before implantation
has several advantages enabling assessment of organ injury, induc-
tion of repair mechanisms, or even allowing optional treatment
during perfusion. This study, using an established DCD kidney
transplantation model, demonstrates 4 important results regarding
2 competitive endischemic machine perfusion approaches, currently
discussed for kidneys.
First, HOPE treatment of DCD kidney is superior to normo-
thermic perfusion, and oxygen is the key ingredient during
hypothermic perfusion, underlining the importance of aerobic mito-
chondrial conditioning before normothermic reperfusion. Second,
endischemic HOPE treatment of DCD kidneys does not provoke
relevant ROS release, in contrast to normothermic perfusion,
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FIGURE 4. Histology of cold-stored DCD kidneys 1 day after machine perfusion and transplantation. Normothermic perfused
kidney transplants displayed high activation of TLR-4 positive tubuli (B, D), while HOPE-treated kidney transplants showed low
amounts of TRL-4 positive tubuli (B, D), and no staining of vWF in glomeruli, similarly to controls (C, E). Perfusion with
deoxygenated perfusate (HNPE) reversed the effects of HOPE (A to E).
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corresponding to earlier results in livers.11 Cellular energy charge is
significantly higher uploaded than normothermic perfusion. Third,
normothermic perfusion of cold-stored DCD kidneys induces an
inflammatory milieu during perfusion and triggers reperfusion injury
by release of ROS already before implantation. The extent of
reperfusion injury during normothermic perfusion depends on the
duration of initial donor warm ischemia. Finally, despite induction of
reperfusion injury, endischemic normothermic perfusion of cold-
stored DCD kidneys is superior to cold storage alone, potentially by
induction of cellular defense mechanisms.
In sharp contrast to other solid organs, machine perfusion for
human kidneys was clinically introduced already 40 years ago.22
However, graft survival benefit between pumped and nonpumped
standard human kidneys was only 4% in a large randomized trial
(94% vs 90% 1 year).4 In addition, convincing data are lacking,
addressing underlying mechanisms of kidney graft protection by
machine perfusion.7 On the basis of this, the overall acceptance of
perfusion systems for kidneys has remained relatively poor in many
centers, despite the fact that the rate of delayed graft function (DGF)
undoubtedly improved by machine kidney perfusion, especially in
ECD grafts.23 Recent studies, however, have triggered a clinical
reinterest in kidney machine perfusion, mainly in UK.5,6,19 These
investigators rely on the simple combination of initial cold storage
applying normothermic perfusion afterwards for a short period
before implantation with ABO-compatible, cross-matched, packed
red blood cells.5,6 Accordingly, current clinical application of this
concept in human showed an impressive reduction of DGF after
kidney transplantation (6% vs 36%), when treated by 1-hour nor-
mothermic perfusion.6 It was stated that endischemic normothermic
perfusion techniques may offer practical advantages and serve as
future alternative form of organ preservation.5 We have developed a
similar endischemic perfusion approach for DCD livers in the last 15
years, but using hypothermic oxygenation with acellular perfusate
instead of normothermic perfusion with diluted blood.13,24 We aimed
therefore to compare the 2 endischemic machine perfusion
approaches in a transplant model with relevant kidney injury,
simulating DCD.
Consistent with above-stated studies,5,6 we found a protective
effect of endischemic normothermic perfusion in DCD kidneys,
compared with cold storage alone. However, we also show that
normothermic perfusion of DCD kidneys induced significant reper-
fusion injury, evident by high amounts of released ROS, DAMPs, and
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endothelial activation. Sustained inflammatory responses are well
known to start during any ischemic insult and accelerate upon
normothermic reperfusion in vivo.25 The mechanisms underlying
activation of immune cells in the postischemic organ involve DAMPs
in conjunction with hypoxia-inducible factors (HIFs) and adhesion
molecules.25 These initiators cause permeability dysfunctions, for
example, of the renal vascular endothelium,26 and trigger release of
chemokines, and activate TLRs.26
We show in this study that normothermic perfusion of ischemic
kidneys induces an inflammatory environment exvivo as a prerequisite
for downstream attracting of macrophages, dentritic cells, and neu-
trophils (Fig. 4G).27 In response to this, cellular defense mechanisms
are upregulated during normothermic perfusion, similar to ischemic
preconditioning, underlined by increased heat shock and HIF-proteins
or proinflammatory cytokines such as TNF-a.28 We would speculate
that induction of repair cellular pathways is responsible for protective
effects of normothermic perfusion compared with cold storage. Of
note, healthy kidneys, not exposed to warm ischemia in donors
(controls), showed minor reperfusion injury during normothermic
perfusion. These results correspond to earlier investigations regarding
normothermic perfusion of nonischemic and ischemic livers.10
Our study demonstrates that HOPE prevents oxidative stress
or DAMPs release during perfusion.8,10,24 In addition, HOPE treat-
ment prevents mitochondrial ROS production and downstream
macrophage and endothelial activation during reperfusion,8,29 poten-
tially by a reversible downregulation of mitochondrial electron
transfer.8 Accordingly, kidney grafts treated by HOPE showed
significant less TLR-4-positive cells, less TNF-a release, less endo-
thelial cell activation after implantation, and were rescued from
lethal injury, in contrast to normothermic perfusion or cold storage
alone. These results are in contrast to studies using nonoxygenated
cold perfusion at relatively high pressure (30mmHg) in pigs,30 but in
line with other previous studies on low pressure oxygenated and
endischemic cold kidney perfusion.31,32 The beneficial effects of
HOPE were completely lost when oxygen in the perfusate was
replaced by nitrogen, pointing to the key function of perfusate
oxygen. Second, we believe that the success of HOPE in kidneys
depends strongly also on low pressure conditions (<20mm Hg),
similar to livers,8 due to a high risk of shear stress and endothelial
damage during cold perfusion of kidneys at a perfusion pressure
>20mm Hg.8,32 On the basis of these observations, the current
clinical practice of DCD kidney perfusion may need to be adapted,
being most frequently continuous cold perfusion using a pressure of
(30/20mm Hg) LifePort Kidney Transporter (Organ Recovery Sys-
tems, Chicago, IL) without active oxygenation.4,7,31
Notably, the difference between both perfusion techniques
appears multifactorial because of several varying parameters, for
example, perfusate composition, temperature, pO2, and perfusion
pressure. The results of this study therefore need to be confirmed
in human by randomized trials. As a second limitation, we did not
investigate upfront normothermic perfusion without any cold ische-
mia. On the basis of this, starting normothermic perfusion already in
donors may lead to different results.33,34 Furthermore, we cannot
exclude that perfusion for >1 hour would have been more effective
(warm and cold).
In summary, although normothermic oxygenated perfusion is
superior to evaluate online organ metabolism,35 it also triggers
reperfusion injury ex vivo, depending on the extent of donor ische-
mia. In contrast, HOPE prevents oxidative stress during implantation,
possibly by mitochondrial repair mechanism.36 As these results are
highly consistent with data in DCD liver grafts treated by HOPE,10
we assume that HOPE serves as general novel strategy to address
ischemic events in any organs. We, therefore, envision a broad
implication of HOPE in the field of transplantation.
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DISCUSSANTS
J. Pirenne (Leuven, Belgium):
Machine perfusion (MP) is a revolution. There is growing
evidence that MP is better than static preservation but there is no
consensus on duration (continuous or delayed) and temperature
(warm or cold) necessary for this protection.
In this article, you show that HOPE a short period of Hypo-
thermic Oxygenated Perfusion after cold storage ameliorates kidneys
exposed to warm and cold ischemia. Interestingly, you presented
similar data in a liver transplant model at this meeting years ago,
showing that HOPE is efficient for both organs.
Original rationale for HOPE (cold/delayed perfusion) is its
simplicity. Let us put the simplicity apart for a moment.
HOPE - through active oxygenation - probably works by
restoring mitochondrial machinery. There are other data (from
Minor) showing that adding O2 to cold storage is beneficial. This
is logical since at 48C there is ongoing metabolism and O2 may
prevent partly the switch from aerobic to anaerobic metabolism.
If O2 is ‘‘good’’ why would not it be better when given
immediately after procurement?
Your warm perfusion group was superior to static storage, but
inferior to cold HOPE. I have difficulty to understand that because
with warm you have the potential to restore mitochondrial machinery
to an even greater extent?
Did you test warm MP immediately after procurement?
Real time assessment of metabolism and function may not be
possible in the cold. This is critical because if you want to increase
the organ pool you want be able to assess function and viability. Can
you comment on that?
Response From P. Dutkowski (Zurich, Switzerland):
Your first question addresses timing of perfusion. In principal,
it appears logical to perfuse upfront organs instead of any cold
storage, but our results show also that this may not be needed, if cold
storage is kept relatively short. In fact, there is no difference between
upfront HOPE and HOPE after 6- to 8-hour cold storage in kidneys
and livers.
The second question targets the effects of normothermic
perfusion on mitochondria. We show in this study that normothermic
perfusion of cold stored DCD kidneys initiates an inflammatory
reaction that triggers reperfusion injury already before implantation,
similarly as seen in normothermic perfused cold stored DCD livers.
Of note, this kind of injury is dependent on the extent of donor warm
ischemia, and is not observed in DBD grafts. In this series of
experiment, we did not test warm perfusion immediately after
procurement in DCD kidneys, which may lead to different results.
Your last question was regarding viability assessment during
HOPE. Currently, it is feasible to measure graft injury by several
markers, but more difficult to measure organ function in the cold.
Further research is needed for advanced analysis of mitochondrial
metabolism during HOPE, which will however be possible in the
future.
T. van Gulik (Amsterdam, The Netherlands):
The step toward upfront continued perfusion using the same
methods as in HOPE also seems a logical step toward optimal organ
preservation. These organs would be cold perfused from the begin-
ning, apart from when there are logistical constraints with machine
perfusion at the site of the donor where the organs are retrieved.
Continuous hypothermic oxygenated perfusion for the duration of
ischemia is another way to proceed, instead of 1 hour of perfusion.
In your second group of rat kidneys, you used normothermic
perfusion at 37-degree celsius. That follows the concept of Lindberg
and Carrel who in 1938 pioneered normothermic perfusion of
organs. We now think that 37 degrees is actually too warm and
we should probably go to sub-normothermic levels. Maybe perfusion
at 28 degrees would give better results, even better than HOPE.
Response From P. Dutkowski (Zurich, Switzerland):
I do not fully agree with your first statement, as in our
experience, there was no advantage of an immediate cold oxygenated
perfusion directly after procurement compared to an endischemic
approach after cold storage. Based on this, we are currently more in
favor of applying HOPE at the transplant center.
Regarding your second comment, the optimal perfusate
temperature for machine perfusion of different organs remains
currently unclear. Further research is needed to evaluate this issue.
P.J. Friend (Oxford, United Kingdom):
We are all trying to minimize the acute inflammatory response
on reperfusion, and clearly there is substantial benefit in delivering
oxygen and repleting ATP stores. Do you feel that the optimal
combination here might actually a progressive re-warming starting
with your oxygenated cold perfusion and progressing toward the
physiological situation, that is, 37 degrees? There are some down-
sides to cooling and it seems to me that you should be able to
optimize the combination in some way.
Response From P. Dutkowski (Zurich, Switzerland):
This is an interesting concept; I do believe that a combination
of cold and warm perfusion techniques could further optimize organ
function, especially in highly injured organs. This would allow
minimizing of early reperfusion injury, for example by initial
HOPE, and further evaluation of organ function during subsequent
normothermic perfusion.
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